Literature DB >> 6217550

Multiple sclerosis: distribution of T cell subsets within active chronic lesions.

U Traugott, E L Reinherz, C S Raine.   

Abstract

The distribution of T cells and T cell subsets was examined within the human central nervous system in active lesions from seven patients with chronic multiple sclerosis. The monoclonal antibodies anti-T11, anti-T4, and anti-T8 were used to detect total (whole) T cells, helper T cells, and suppressor-cytotoxic T cells, respectively, and a monoclonal antibody against human Ia was used for macrophages and B cells. Lesion progression was associated with large numbers of T4+ cells at the lesion margin and these extended great distances into the adjacent normal-appearing white matter. T8+ cells were most commonly concentrated around the lesion margin and displayed a preferential perivascular distribution. Within the lesion center, only a few T cells were found. Ia+ macrophages were most numerous within the centers of active lesions and were always present in the adjacent normal white matter. The monoclonal antibodies to T cells did not cross-react with glial cells including oligodendrocytes. These results indicate that T4+ cells are actively involved in lesion extension and Ia+ cells, in demyelination.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6217550     DOI: 10.1126/science.6217550

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  118 in total

1.  Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions.

Authors:  K W Wucherpfennig; J Newcombe; H Li; C Keddy; M L Cuzner; D A Hafler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

Review 2.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis.

Authors:  Nathan R York; Jason P Mendoza; Sterling B Ortega; Andrew Benagh; Andrew F Tyler; Mihail Firan; Nitin J Karandikar
Journal:  J Autoimmun       Date:  2010-02-20       Impact factor: 7.094

4.  Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis.

Authors:  Alfredo Prieto; David Díaz; Hugo Barcenilla; Carmen Castrillo; Jorge Monserrat; Antonio García Merino; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

5.  A lymphocyte homing receptor (L-selectin) mediates the in vitro attachment of lymphocytes to myelinated tracts of the central nervous system.

Authors:  K Huang; J S Geoffroy; M S Singer; S D Rosen
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

6.  Interleukin 2 mediates the inhibition of oligodendrocyte progenitor cell proliferation in vitro.

Authors:  R P Saneto; A Altman; R L Knobler; H M Johnson; J de Vellis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Dual expression of CD45RA and CD45RO isoforms on myelin basic protein-specific CD4+ T-cell lines in multiple sclerosis.

Authors:  Y Qin; S Van Den Noort; J Kurt; S Gupta
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

8.  Decreased RORC-dependent silencing of prostaglandin receptor EP2 induces autoimmune Th17 cells.

Authors:  David M Kofler; Alexander Marson; Margarita Dominguez-Villar; Sheng Xiao; Vijay K Kuchroo; David A Hafler
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

9.  Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis.

Authors:  Subhajit Dasgupta; Malabendu Jana; Xiaojuan Liu; Kalipada Pahan
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

Review 10.  Oligodendroglial response to the immune cytokine interferon gamma.

Authors:  B Popko; K D Baerwald
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.